6533b821fe1ef96bd127b5eb

RESEARCH PRODUCT

hTERT mRNA expression in urine as a useful diagnostic tool in bladder cancer. Comparison with cytology and NMP22 BladderCheck Test®

S. Aliño-pellicerM.j. Herrero-cerveraJosé María Martínez-jabaloyasJ.a. March-villalbaJorge Panach-navarrete

subject

medicine.medical_specialtyBladder cancermedicine.diagnostic_testbusiness.industryUrinary system030232 urology & nephrologyUrologyGeneral MedicineUrineCystoscopymedicine.diseaselaw.invention03 medical and health sciencesHtert mrna0302 clinical medicineRandomized controlled triallaw030220 oncology & carcinogenesisCytologymedicineTelomerase reverse transcriptasebusiness

description

Abstract Introduction To study the relationship between quantitative mRNA determination (hTERT) in patients with bladder tumor, history of bladder tumor, and in subjects without a history of this neoplasia. Material and methods A prospective randomized controlled study with 91 subjects included. The value of mRNA-hTERTN was determined in 63 patients with a history or suspicion of bladder tumor and in 28 controls. Urine samples were sent for evaluation of the mRNA level (hTERT), the cytological study and the NMP22 result. Results Differences were observed in mean hTERTN levels in each of the groups: tumor presence 21.33 ± 40.66, tumor history 2.16 ± 2.67, controls 0.9 ± 1.75 (p  Conclusions hTERTN mRNA levels in urine were higher in patients with bladder tumors compared to patients with a history of bladder tumor and with negative cystoscopy, as well as in the control group. This determination showed a higher diagnostic yield compared with the detection of NMP22 and urinary cytology.

yearjournalcountryeditionlanguage
2018-10-01Actas Urológicas Españolas (English Edition)
https://doi.org/10.1016/j.acuroe.2018.07.006